Cutaneous Mastocytosis – Clinical HeterogeneityHartmann K.a · Henz B.M.b
aDepartment of Dermatology, University Hospital, Cologne, and bDepartment of Dermatology and Allergy, Charité, Humboldt University, Berlin, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Cutaneous mastocytosis (CM) encompasses several distinct patterns of disease which can be distinguished by the type of skin lesions, age of onset, familial occurrence, noncutaneous involvement, associated c-kit mutations, and prognosis. A clear distinction of the type of CM in individual patients has important implications regarding patient management and prognosis.
© 2002 S. Karger AG, Basel
- Weber S, Krüger-Krasagakes S, Grabbe J, Zuberbier T, Czarnetzki BM: Mast cells. Int J Dermatol 1995;34:1–10.
Hartmann K, Henz BM: Classification of cutaneous mastocytosis: A modified consensus proposal. Leuk Res, in press.
- Hartmann K, Henz BM: Mastocytosis: Recent advances in defining the disease. Br J Dermatol 2001;144:682–695.
- Wolff K, Komar M, Petzelbauer P: Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001;25:519–528.
- Valent P, Horny H, Escribano L, Longley BJ, Chin YL, Schwartz LB, Marone G, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM: Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 2001;25:603–625.
- Hannaford R, Rogers M: Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol 2001;42:15–21.
Haas N, Henz BM: Mastocytosis (urticaria pigmentosa); in Henz BM, Zuberbier T, Grabbe J, Monroe E (eds): Urticaria – Clinical, Diagnostic and Therapeutic Aspects. Berlin, Springer, 1998, pp 125–138.
- Kalayciyan AK, Kotogyan A: Teleangiectasia macularis eruptiva perstans. J Eur Acad Dermatol Venereol 2001;15:263–264.
- Büttner C, Grabbe J, Haas N, Sepp NT, Henz BM: Comparison of genetic and immunohistochemical findings in childhood- and adult-onset urticaria pigmentosa. Int Arch Allergy Immunol 1999;118:206–207.
- Fearfield LA, Francis N, Henry K, Costelle C, Bunker CB: Bone marrow involvement in cutaneous mastocytosis. Br J Dermatol 2001;144:561–566.
- Czarnetzki BM, Kolde G, Schoemann A, Urbanitz S, Urbanitz D: Bone marrow findings in adult patients with urticaria pigmentosa. J Am Acad Dermatol 1988;18:45–51.
- Rodermund OE, Klingmueller G, Rohner H-G: Interne Befunde bei Mastozytose. Hautarzt 1980;31:175–178.
- Büttner C, Henz BM, Sepp N, Grabbe J: Identification of an activating c-kit mutation in adult- but not in childhood onset indolent mastocytosis: A possible explanation for divergent clinical behavior. J Invest Dermatol 1998;111:1227–1231.
- Czarnetzki BM, Behrendt H: Urticaria pigmentosa: Clinical picture and response to oral disodiumcromoglycate. Br J Dermatol 1981;105:563–568.
- Husak R, Blume-Peytavi U, Pfrommer C, Geilen CC, Goerdt S, Orfanos CE: Nodular and bullous cutaneous mastocytosis of the xanthelasmoid type: Case report. Br J Dermatol 2001;144:355–358.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.